SCHEMBL952616

SCHEMBL952616

COC(=O)c1cc(C)c2occc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.44
▸ LMNA P02545 4/20 0.44
▸ TDP1 Q9NUW8 3/20 0.44
▸ GAA P10253 3/20 0.44
▸ XDH P47989 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ FUT7 Q11130 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ ACVR1 Q04771 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ ALOX15 P16050 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ PTPN11 Q06124 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28183652 0.83 KDM4E (0.47) KDM4ELMNATDP1GAAXDH
SCHEMBL28182937 0.83 ACVR1 (0.51) KDM4ELMNATDP1GAAXDH
SCHEMBL5987396 0.83 NOTUM (0.44) KDM4ELMNATDP1GAAXDH
SCHEMBL20876274 0.79 ACVR1 (0.41) KDM4ELMNATDP1GAAXDH
SCHEMBL5988003 0.78 ACVR1 (0.41) KDM4ELMNATDP1GAAXDH
SCHEMBL28513149 0.78 ACVR1 (0.41) KDM4ELMNATDP1GAAXDH
SCHEMBL23616986 0.75 ALDH1A1 (0.46) KDM4ELMNATDP1GAAXDH
SCHEMBL28507007 0.75 ACVR1 (0.39) KDM4ELMNATDP1GAAXDH
SCHEMBL5987881 0.75 ACVR1 (0.39) KDM4ELMNATDP1GAAXDH
SCHEMBL29284859 0.74 CYP3A4 (0.41) KDM4EPOLBALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875645-B2 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders HOFFMAN-LA ROCHE INC. (US) 2011-01-25 — — US disclosed
EP-1981497-A2 USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-22 — — EP disclosed
US-20070197621-A1 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 — — US disclosed
WO-2007085557-A2 USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197621-A1 Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives GPR119, PER2, MTNR1B KDM4E 1531/4885LMNA 2048/4885TDP1 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback